Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7) 7
adult (6) 6
aged (6) 6
female (6) 6
index medicus (6) 6
middle aged (6) 6
oncology (6) 6
aged, 80 and over (5) 5
male (5) 5
cancer (3) 3
cetuximab (3) 3
colorectal cancer (3) 3
colorectal neoplasms - drug therapy (3) 3
disease-free survival (3) 3
fluorouracil (3) 3
fluorouracil - administration & dosage (3) 3
hematology, oncology and palliative medicine (3) 3
leucovorin (3) 3
research (3) 3
survival (3) 3
1st-line treatment (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
carcinoma (2) 2
care and treatment (2) 2
cetuximab plus irinotecan (2) 2
chemotherapy (2) 2
cisplatin (2) 2
colorectal neoplasms - genetics (2) 2
colorectal neoplasms - mortality (2) 2
colorectal neoplasms - pathology (2) 2
digestive system diseases (2) 2
endothelial growth-factor (2) 2
follow-up studies (2) 2
genetics (2) 2
head and neck cancer (2) 2
leucovorin - administration & dosage (2) 2
medicine, research & experimental (2) 2
metastasis (2) 2
molecular biology (2) 2
neoplasm staging (2) 2
oxaliplatin (2) 2
proto-oncogene proteins - genetics (2) 2
proto-oncogene proteins p21 (2) 2
ras proteins - genetics (2) 2
signal transduction (2) 2
studies (2) 2
survival rate (2) 2
trial (2) 2
abridged index medicus (1) 1
activation (1) 1
acute coronary syndromes (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
aflibercept (1) 1
angiogenesis (1) 1
antibodies - administration & dosage (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
atherosclerosis (1) 1
atherosclerosis - etiology (1) 1
atherosclerosis - metabolism (1) 1
atherosclerosis - pathology (1) 1
bevacizumab (1) 1
biochemistry (1) 1
biochemistry, medical (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - genetics (1) 1
breast neoplasms - pathology (1) 1
cancer research (1) 1
cancer therapies (1) 1
carcinoma, ductal, breast - drug therapy (1) 1
carcinoma, ductal, breast - genetics (1) 1
carcinoma, ductal, breast - pathology (1) 1
carcinoma, hepatocellular - drug therapy (1) 1
carcinoma, hepatocellular - mortality (1) 1
carcinoma, hepatocellular - pathology (1) 1
carcinoma, intraductal, noninfiltrating - drug therapy (1) 1
carcinoma, intraductal, noninfiltrating - genetics (1) 1
carcinoma, intraductal, noninfiltrating - pathology (1) 1
carcinoma, lobular - drug therapy (1) 1
carcinoma, lobular - genetics (1) 1
carcinoma, lobular - pathology (1) 1
carcinoma, squamous cell (1) 1
carcinoma, squamous cell - drug therapy (1) 1
carcinoma, squamous cell - pathology (1) 1
cardiovascular disease (1) 1
cardiovascular-disease (1) 1
cell biology (1) 1
cell culture (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
by Tabernero, Josep, Dr and Yoshino, Takayuki, MD and Cohn, Allen Lee, MD and Obermannova, Radka, MD and Bodoky, Gyorgy, Prof and Garcia-Carbonero, Rocio, MD and Ciuleanu, Tudor-Eliade, Prof and Portnoy, David C, MD and Van Cutsem, Eric, Prof and Grothey, Axel, MD and Prausová, Jana, MD and Garcia-Alfonso, Pilar, PhD and Yamazaki, Kentaro, MD and Clingan, Philip R, Prof and Lonardi, Sara, MD and Kim, Tae Won, Prof and Simms, Lorinda, MS and Chang, Shao-Chun, PhD and Nasroulah, Federico, MD and RAISE Study Investigators
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Summary Background Angiogenesis is an important therapeutic target in colorectal carcinoma. Ramucirumab is a human IgG-1 monoclonal antibody that targets the... 
Hematology, Oncology and Palliative Medicine | TRIAL | SURVIVAL | LEUCOVORIN | ONCOLOGY | IRINOTECAN | AFLIBERCEPT | FLUOROURACIL | CANCER | ENDOTHELIAL GROWTH-FACTOR | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Bevacizumab | Disease-Free Survival | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Antibodies, Monoclonal - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Camptothecin - analogs & derivatives | Antimitotic agents | Care and treatment | Carcinoma | Endothelial growth factors | Colorectal cancer | Monoclonal antibodies | Development and progression | Metastasis | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
by Zhu, Andrew X, Dr and Park, Joon Oh, MD and Ryoo, Baek-Yeol, MD and Yen, Chia-Jui, MD and Poon, Ronnie, MD and Pastorelli, Davide, MD and Blanc, Jean-Frederic, MD and Chung, Hyun Cheol, MD and Baron, Ari D, MD and Pfiffer, Tulio Eduardo Flesch, MD and Okusaka, Takuji, MD and Kubackova, Katerina, MD and Trojan, Jorg, MD and Sastre, Javier, PhD and Chau, Ian, MD and Chang, Shao-Chun, MD and Abada, Paolo B, MD and Yang, Ling, MS and Schwartz, Jonathan D, MD and Kudo, Masatoshi, MD and REACH Trial Investigators
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 859 - 870
Summary Background VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MONOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Liver Neoplasms - mortality | Patient Selection | Dose-Response Relationship, Drug | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Remission Induction | Disease-Free Survival | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen
by Soulières, Denis and Aguilar, Jose Luis and Chen, Eric and Misiukiewicz, Krzysztof and Ernst, Scott and Lee, Hyun Jung and Bryant, Katherine and He, Shuang and Obasaju, Coleman K and Chang, Shao-Chun and Chin, Steve and Adkins, Douglas
BMC Cancer, ISSN 1471-2407, 01/2016, Volume 16, Issue 1, p. 19
Background: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the first-line treatment of recurrent/metastatic... 
Carcinoma, squamous cell | Head and neck cancer | Safety | Cetuximab | Carcinoma | CISPLATIN | ONCOLOGY | squamous cell | CANCER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local - drug therapy | Male | Platinum - administration & dosage | Chemistry, Pharmaceutical | Cetuximab - adverse effects | Cisplatin - administration & dosage | Head and Neck Neoplasms - pathology | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - drug therapy | Fluorouracil - administration & dosage | Adult | Cetuximab - administration & dosage | Female | Aged | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Antineoplastic agents | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer
by Urba, Susan and van Herpen, Carla M. L and Sahoo, Tarini Prasad and Shin, Dong M and Licitra, Lisa and Mezei, Klara and Reuter, Christoph and Hitt, Ricardo and Russo, Francesca and Chang, Shao‐Chun and Hossain, Anwar M and Frimodt‐Moller, Bente and Koustenis, Andrew and Hong, Ruey‐Long
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 19, pp. 4694 - 4705
BACKGROUND: Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) is associated with poor survival. Platinum‐based chemotherapy is often... 
clinical trial | phase 3 | pemetrexed | head and neck cancer | cisplatin | THYMIDYLATE SYNTHASE | PHASE-III | GUIDELINES | METHOTREXATE | TRIAL | PERFORMANCE STATUS ASSESSMENT | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | COMPARING CISPLATIN | COOPERATIVE-ONCOLOGY-GROUP | PLUS FLUOROURACIL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Malondialdehyde mediates oxidized LDL-induced coronary toxicity through the Akt-FGF2 pathway via DNA methylation
by Yang, Tzu-Ching and Chen, Yi-Jie and Chang, Shwu-Fen and Chen, Chu-Huang and Chang, Po-Yuan and Lu, Shao-Chun
Journal of Biomedical Science, ISSN 1021-7770, 02/2014, Volume 21, Issue 1, pp. 11 - 11
Background: Oxidized LDL (oxLDL) is involved in the development of atherosclerotic heart disease through a mechanism that is not fully understood. In this... 
Signal transduction | Lipoproteins | Lipid oxidation | DNA methylation | Epigenetics | Malondialdehyde (MDA) | Gene expression | MEDICINE, RESEARCH & EXPERIMENTAL | MYOCARDIAL-INFARCTION | ELECTRONEGATIVE LDL | EPIGENETIC MODIFICATIONS | LOW-DENSITY-LIPOPROTEIN | ATHEROSCLEROSIS | FIBROBLAST-GROWTH-FACTOR | G-PROTEIN | ENDOTHELIAL-CELLS | GENE-EXPRESSION | CARDIOVASCULAR-DISEASE | Malondialdehyde - metabolism | Cell Survival - drug effects | Atherosclerosis - pathology | Endothelial Cells - metabolism | Humans | Oxidative Stress - genetics | DNA Methylation - genetics | Atherosclerosis - metabolism | Proto-Oncogene Proteins c-akt - genetics | Coronary Vessels - metabolism | Antibodies - administration & dosage | Atherosclerosis - etiology | Lipoproteins, LDL - toxicity | Fibroblast Growth Factor 2 - genetics | Coronary Vessels - cytology | Endothelial Cells - cytology | Malondialdehyde - immunology | DNA - biosynthesis | Lipoproteins, LDL - metabolism | Oxidative Stress - drug effects | Malondialdehyde - antagonists & inhibitors | Oxidative stress | Cell culture | Toxicity | Genes | Clinical trials | Cardiovascular disease | Cytotoxicity | Cholesterol | Proteins | Medicine | Studies | Cell growth | Hospitals | Atherosclerosis | Acute coronary syndromes | Homocysteine | Deoxyribonucleic acid--DNA | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Validation of companion diagnostic for detection of mutations in Codons 12 and 13 of the KRAS gene in patients with metastatic colorectal Cancer: Analysis of the NCIC CTG CO.17 trial
by Harbison, Christopher T and Horak, Christine E and Ledeine, Jean-Marie and Mukhopadhyay, Pralay and Malone, Daniel P and O'Callaghan, Chris and Jonker, Derek J and Karapetis, Christos S and Khambata-Ford, Shirin and Gustafson, Nancy and Trifan, Ovidiu C and Chang, Shao-Chun and Ravetto, Paul and Green IV, George A
Archives of Pathology and Laboratory Medicine, ISSN 0003-9985, 06/2013, Volume 137, Issue 6, pp. 820 - 827
Context.-The therascreen KRAS RGQ polymerase chain reaction kit is being developed as a companion diagnostic to aid clinicians, through detection of KRAS... 
SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | LEUCOVORIN | CETUXIMAB PLUS IRINOTECAN | OXALIPLATIN | MEDICAL LABORATORY TECHNOLOGY | PATHOLOGY | FLUOROURACIL | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Codon - genetics | Cetuximab | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Proto-Oncogene Proteins - genetics | Survival Rate | Codon, Nonsense | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Aged | Mutation | Colorectal Neoplasms - pathology | Adenocarcinoma - mortality | Care and treatment | Genetic aspects | Metastasis | Research | Colorectal cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Enhanced Resistance to Tamoxifen by the c-ABL Proto-oncogene in Breast Cancer
by Zhao, Huajun and Ou-Yang, Fu and Chen, I-Fen and Hou, Ming-Feng and Yuan, Shyng-Shiou F and Chang, Hsueh-Ling and Lee, Yi-Chen and Plattner, Rina and Waltz, Susan E and Ho, Shuk-Mei and Sims, Jonathan and Wang, Shao-Chun
Neoplasia, ISSN 1476-5586, 03/2010, Volume 12, Issue 3, pp. 214,IN1 - 223,IN3
Targeting the estrogen receptor is an important strategy in breast cancer therapy. However, although inhibiting estrogen receptor function with specific... 
CELLS | ACTIVATION | INHIBITION | THERAPY | ONCOLOGY | PHOSPHORYLATION | TYROSINE KINASE | DNA-DAMAGE | GROWTH | FAMILY KINASES | MECHANISMS | Carcinoma, Ductal, Breast - genetics | Carcinoma, Lobular - pathology | Tissue Array Analysis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | Carcinoma, Intraductal, Noninfiltrating - genetics | Receptors, Progesterone - genetics | Receptors, Progesterone - metabolism | Carcinoma, Ductal, Breast - drug therapy | Carcinoma, Lobular - genetics | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Adult | Carcinoma, Ductal, Breast - pathology | Estrogen Receptor alpha - metabolism | Female | Genes, abl - physiology | Signal Transduction | RNA, Small Interfering - pharmacology | Gene Silencing | Carcinoma, Intraductal, Noninfiltrating - drug therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Carcinoma, Intraductal, Noninfiltrating - pathology | Estrogen Receptor alpha - genetics | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Cell Line, Tumor | Aged | Carcinoma, Lobular - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay
by Chang, Shao-Chun and Denne, Jonathan and Zhao, Luping and Horak, Christine and Green, George and Khambata-Ford, Shirin and Bray, Christopher and Celik, Ilhan and Van Cutsem, Eric and Harbison, Christopher
Clinical Colorectal Cancer, ISSN 1533-0028, 2013, Volume 12, Issue 3, pp. 195 - 203.e2
Micro-Abstract Kirsten rat sarcoma virus ( KRAS ) wild-type status determined using a locked nucleic acid (LNA)-mediated quantitative polymerase chain reaction... 
Hematology, Oncology and Palliative Medicine | Gastroenterology and Hepatology | KRAS | EGFR inhibitors | Cetuximab | Mutation assay | Colorectal cancer | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | EFFICACY | OXALIPLATIN | FLUOROURACIL | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | K-RAS MUTATIONS | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Follow-Up Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Oligonucleotides | Male | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Polymerase Chain Reaction | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Genotype | Proto-Oncogene Proteins - genetics | Survival Rate | Mutation - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | DNA, Neoplasm - genetics | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Identification and characterization of genes encoding phospholipid biosynthetic enzymes of Saccharomyces cerevisiae
by Chang, Shao-Chun
01/1998, ISBN 0591807432
Phospholipids are the major component of cellular membranes. In addition to its structural role, phospholipids play an active and diverse role in cellular... 
Cellular biology | Genetics | Biochemistry | Molecular biology
Dissertation
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.